Rigel Highlights New GAVRETO® (pralsetinib) Data Across RET Fusion-Positive Cancers in Oral and Poster Presentations at ESMO Congress 2026

ConferencepositiveGAVRETOPositive

AI Analysis

Summary

Rigel highlighted new GAVRETO (pralsetinib) data in oral and poster presentations at ESMO Congress 2026, including a pooled ARROW and TAPISTRY analysis showing a 53% overall response rate in RET fusion-positive solid tumors. Additional analyses covered first-line outcomes and patient-reported quality of life in RET fusion-positive NSCLC.

Clinical Trial Data

Outcome Details

Pooled ARROW and TAPISTRY analysis showed a 53% overall response rate in patients with RET fusion-positive solid tumors; additional analyses presented on first-line outcomes and patient-reported quality of life in RET fusion-positive NSCLC.

Importance:5/10

Sentiment:

0.50

ESMO 2026GAVRETOpralsetinibRET fusionNSCLCsolid tumorsoncologyconference presentationpooled analysisARROW

Related Companies

$RIGL

Read the original article

Published by PR Newswire Pharma on October 19, 2026 12:05 PM

Read Original